PPARγ Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention : A Pilot Study
المؤلفون المشاركون
Schaefer, Katherine L.
Hosono, Kunihiro
Nakajima, Atsushi
Takahashi, Hirokazu
Endo, Hiroki
Maeda, Shin
Sugiyama, Michiko
Uchiyama, Takashi
Nakagama, Hitoshi
Sakai, Eiji
المصدر
العدد
المجلد 2010، العدد 2010 (31 ديسمبر/كانون الأول 2010)، ص ص. 1-4، 4ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2010-08-02
دولة النشر
مصر
عدد الصفحات
4
التخصصات الرئيسية
العلوم الطبيعية والحياتية (متداخلة التخصصات)
الأحياء
الملخص EN
Activating synthetic ligands for peroxisome proliferator-activated receptor gamma (PPARγ), such as pioglitazone, are commonly used to treat persons with diabetes mellitus with improvement of insulin resistance.
Several reports have clearly demonstrated that PPARγ ligands could inhibit colorectal cancer cell growth and induce apoptosis.
Meanwhile, aberrant crypt foci (ACF) have come to be established as a biomarker of the risk of CRC in azoxymethane-treated mice and rats.
In humans, ACF can be detected using magnifying colonoscopy.
Previously, CRC and adenoma were used as a target for chemopreventive agents, but it needs a long time to evaluate, however, ACF can be a surrogate marker of CRC even for a brief period.
In this clinical study, we investigated the chemopreventive effect of pioglitazone on the development of human ACF as a surrogate marker of CRC.
Twenty-nine patients were divided into two groups, 20 were in the endoscopically normal control group and 9 were in the pioglitazone (15 mg/day) group, and ACF and adenoma were examined before and after 1-month treatment.
The number of ACF was significantly decreased (5.8±1.1 to 3.3±2.3) after 1 month of pioglitazone treatment, however, there was no significant change in the number of crypts/ACF or in the number and size of adenomas.
Pioglitazone may have a clinical application as a cancer-preventive drug.
This investigation is just a pilot study, therefore, further clinical studies are needed to show that the PPARγ ligand may be a promising candidate as a chemopreventive agent for colorectal carcinogenesis.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Takahashi, Hirokazu& Hosono, Kunihiro& Uchiyama, Takashi& Sugiyama, Michiko& Sakai, Eiji& Endo, Hiroki…[et al.]. 2010. PPARγ Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention : A Pilot Study. PPAR Research،Vol. 2010, no. 2010, pp.1-4.
https://search.emarefa.net/detail/BIM-458006
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Takahashi, Hirokazu…[et al.]. PPARγ Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention : A Pilot Study. PPAR Research No. 2010 (2010), pp.1-4.
https://search.emarefa.net/detail/BIM-458006
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Takahashi, Hirokazu& Hosono, Kunihiro& Uchiyama, Takashi& Sugiyama, Michiko& Sakai, Eiji& Endo, Hiroki…[et al.]. PPARγ Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention : A Pilot Study. PPAR Research. 2010. Vol. 2010, no. 2010, pp.1-4.
https://search.emarefa.net/detail/BIM-458006
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-458006
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر